Edgar P Simard1, Ruth M Pfeiffer, Eric A Engels. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA.
Abstract
OBJECTIVE: Deaths related to HIV/AIDS have declined due to improved HIV therapies. However, people with AIDS remain at elevated risk for cancer and cancer deaths. Prior studies evaluated cancer deaths using death certificates, which may be inaccurate. We utilized population attributable risk methods (which do not rely on death certificates) to assess cancer mortality. DESIGN: Data from a US population-based record linkage study were used to identify incident cancers and deaths in 372 364 people with AIDS (1980-2006) followed for up to 5 years after AIDS onset. We utilized Cox regression to compare mortality in individuals with and without cancer and to calculate cancer-attributable mortality across calendar periods (AIDS onset in 1980-1989, 1990-1995, and 1996-2006). RESULTS: Mortality declined across calendar periods for all people with AIDS but remained higher among those with cancer relative to those without. During 1996-2006, among individuals with an AIDS-defining cancer (ADC) who died, 88.3% of deaths were attributable to their ADC; likewise, among individuals with a non-AIDS-defining cancer (NADC), 87.1% of deaths were attributable to their NADC. The fraction of all deaths in people with AIDS attributable to ADC (i.e. population-attributable risk) decreased significantly from 6.3% (1980-1990) to 3.9% (1996-2006), but NADC population attributable mortality increased significantly over time from 0.5% (1980-1989) to 2.3% (1996-2006). CONCLUSION: Among individuals with AIDS and cancer who subsequently die, most deaths are attributable to cancer. With a decline in overall mortality, the proportion of all deaths attributable to NADCs has increased. These results highlight the need for improved cancer prevention and treatment.
OBJECTIVE: Deaths related to HIV/AIDS have declined due to improved HIV therapies. However, people with AIDS remain at elevated risk for cancer and cancer deaths. Prior studies evaluated cancer deaths using death certificates, which may be inaccurate. We utilized population attributable risk methods (which do not rely on death certificates) to assess cancer mortality. DESIGN: Data from a US population-based record linkage study were used to identify incident cancers and deaths in 372 364 people with AIDS (1980-2006) followed for up to 5 years after AIDS onset. We utilized Cox regression to compare mortality in individuals with and without cancer and to calculate cancer-attributable mortality across calendar periods (AIDS onset in 1980-1989, 1990-1995, and 1996-2006). RESULTS: Mortality declined across calendar periods for all people with AIDS but remained higher among those with cancer relative to those without. During 1996-2006, among individuals with an AIDS-defining cancer (ADC) who died, 88.3% of deaths were attributable to their ADC; likewise, among individuals with a non-AIDS-defining cancer (NADC), 87.1% of deaths were attributable to their NADC. The fraction of all deaths in people with AIDS attributable to ADC (i.e. population-attributable risk) decreased significantly from 6.3% (1980-1990) to 3.9% (1996-2006), but NADC population attributable mortality increased significantly over time from 0.5% (1980-1989) to 2.3% (1996-2006). CONCLUSION: Among individuals with AIDS and cancer who subsequently die, most deaths are attributable to cancer. With a decline in overall mortality, the proportion of all deaths attributable to NADCs has increased. These results highlight the need for improved cancer prevention and treatment.
Authors: Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar Journal: AIDS Date: 2006-08-01 Impact factor: 4.177
Authors: J J Goedert; T R Coté; P Virgo; S M Scoppa; D W Kingma; M H Gail; E S Jaffe; R J Biggar Journal: Lancet Date: 1998-06-20 Impact factor: 79.321
Authors: Aaron P Thrift; Jennifer R Kramer; Christine M Hartman; Kathryn Royse; Peter Richardson; Yongquan Dong; Suchismita Raychaudhury; Roxanne Desiderio; Dina Sanchez; Sharmila Anandasabapathy; Donna L White; Elizabeth Y Chiao Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: Catherine de Martel; Meredith S Shiels; Silvia Franceschi; Edgar P Simard; Jérôme Vignat; H Irene Hall; Eric A Engels; Martyn Plummer Journal: AIDS Date: 2015-10-23 Impact factor: 4.177
Authors: David J Riedel; Evelyn Ivy W Mwangi; Lori E Fantry; Carla Alexander; Mian B Hossain; C David Pauza; Robert R Redfield; Bruce L Gilliam Journal: AIDS Date: 2013-04-24 Impact factor: 4.177
Authors: Gita Suneja; Meredith S Shiels; Rory Angulo; Glenn E Copeland; Lou Gonsalves; Anne M Hakenewerth; Kathryn E Macomber; Sharon K Melville; Eric A Engels Journal: J Clin Oncol Date: 2014-06-30 Impact factor: 44.544
Authors: Satish Gopal; Chad J Achenbach; Elizabeth L Yanik; Dirk P Dittmer; Joseph J Eron; Eric A Engels Journal: J Clin Oncol Date: 2014-02-18 Impact factor: 44.544
Authors: Hamish McManus; Kathy Petoumenos; Katherine Brown; David Baker; Darren Russell; Tim Read; Don Smith; Lynne Wray; Michelle Giles; Jennifer Hoy; Andrew Carr; Matthew G Law Journal: Antivir Ther Date: 2014-11-07
Authors: Eric A Engels; Elizabeth L Yanik; Willian Wheeler; M John Gill; Meredith S Shiels; Robert Dubrow; Keri N Althoff; Michael J Silverberg; John T Brooks; Mari M Kitahata; James J Goedert; Surbhi Grover; Angel M Mayor; Richard D Moore; Lesley S Park; Anita Rachlis; Keith Sigel; Timothy R Sterling; Jennifer E Thorne; Ruth M Pfeiffer Journal: Clin Infect Dis Date: 2017-08-15 Impact factor: 9.079